<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16803">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02130609</url>
  </required_header>
  <id_info>
    <org_study_id>CYN13-SkinTel-Elite+-01</org_study_id>
    <nct_id>NCT02130609</nct_id>
  </id_info>
  <brief_title>Skintel Integration Study</brief_title>
  <official_title>Skintel Integration Study for Use With the Elite+ Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to improve the treatment guidelines for the Elite+ by
      determining the maximum safe settings for skin and correlate them to measurement of Melanin
      Index (MI) (MI).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>improve the treatment guidelines for the Elite+ by determining the maximum safe settings for skin and correlate them to measurement of Melanin Index</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Skin Type From I-VI on Non-hair Bearing Skin</condition>
  <arm_group>
    <arm_group_label>Skintel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Skintel</intervention_name>
    <arm_group_label>Skintel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Able to read, understand, and sign the Informed Consent Form

          -  Willing and able to comply with all study requirements

        Exclusion Criteria:

          -  Hypersensitivity to light in the near infrared wavelength region

          -  Sun-damaged skin (treatment contraindicated with Alex laser only)

          -  Unprotected sun exposure (for Alex laser within four weeks of treatment; for

          -  Nd:YAG laser within one week of treatment), including the use of tanning beds or

          -  tanning products, such as creams, lotions and sprays

          -  Take medication which is known to increase sensitivity to sunlight

          -  Seizure disorders triggered by light

          -  Take anticoagulants

          -  Take or have taken oral isotretinoin, such as AccutaneÂ®, within the last six months

          -  Take medication that alters the wound-healing response

          -  History of healing problems or history of keloid formation

          -  Active localized or systemic infection, or an open wound in area being treated

          -  Significant systemic illness or an illness localized in area being treated

          -  History of skin cancer or suspicious lesions

          -  Lupus

          -  Have received or are receiving or gold therapy

          -  Pregnancy, planning on becoming pregnant or have been pregnant recently
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Doherty, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
